8月20日诺华集团宣布创新产品诺锐达(盐酸阿曲生坦片)获得国家药品监督管理局批准用于降低有疾病快速进展风险的原发性免疫球

智通财经
Aug 20
8月20日诺华集团宣布创新产品诺锐达(盐酸阿曲生坦片)获得国家药品监督管理局批准用于降低有疾病快速进展风险的原发性免疫球蛋白A肾病(IgA肾病)成人患者的蛋白尿。据介绍诺锐达是中国首个获批治疗IgA肾病的非免疫性疗法是国内首个且目前唯一针对该适应症的高选择性内皮素A(ETA)受体拮抗剂。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10